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Background: Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable
early-stage breast cancer. It would be advantageous to determine the chemosensitivity of tumors before initiating
NAC. One of the parameters potentially compromising such chemosensitivity would be a hypoxic microenvironment
of cancer cells. The aim of this study was thus to clarify the correlation between expression of the hypoxic marker
carbonic anhydrase-9 (CA9) and chemosensitivity to NAC as well as prognosis of breast cancer patients.
Methods: A total of 102 patients with resectable early-stage breast cancer was treated with NAC consisting of FEC
(5-fluorouracil, epirubicin, and cyclophosphamide) followed by weekly paclitaxel before surgery. Core needle biopsy (CNB)
specimens and resected tumors were obtained from all patients before and after NAC, respectively. Chemosensitivity to
NAC and the prognostic potential of CA9 expression were evaluated by immunohistochemistry.
Results: CA9 positivity was detected in the CNB specimens from 47 (46%) of 102 patients. The CA9 expression in CNB
specimens was significantly correlated with pathological response, lymph node metastasis, and lymph-vascular invasion.
Multivariate analysis revealed that the CA9 expression in CNB specimens was an independent predictive factor for
pathological response. The Kaplan-Meier survival curve revealed a significant negative correlation (p = 0.013) between the
disease-free survival (DFS) and the CA 9 expression in resected tissues after NAC. Multivariate regression analyses indicated
that the CA9 expression in resected tissues was an independent prognostic factor for DFS.
Conclusions: CA9 expression in CNB specimens is a useful marker for predicting chemosensitivity, and CA9 expression in
resected tissue is prognostic of DFS in patients with resectable early-stage breast cancer treated by sequential FEC and
weekly paclitaxel prior to resection.
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Neoadjuvant chemotherapy (NAC) increases the rate of
breast-conserving surgery and decreases the risk of post-
operative recurrence as effectively as adjuvant chemother-
apy; thus, it might be considered to enhance survival [1,2].
For this reason, NAC has been one of the standard care
regimens for patients with various types of carcinomas,* Correspondence: m9312510@med.osaka-cu.ac.jp
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reproduction in any medium, provided the orincluding resectable early-stage breast cancer [3]. The op-
timal regimen for NAC in breast cancer involves a se-
quential or concomitant anthracycline-containing regimen
and taxane [4,5]. The aim of NAC for breast cancer is to
reduce the size of the primary tumor, thereby increasing
the likelihood of breast conservation [6], and might allow
evaluation of the therapeutic effects that facilitate the
strategies of post-operative chemotherapy [7]. Recent
studies have demonstrated that the response status after
NAC is correlated with improved disease-free survival
(DFS) and overall survival (OS) in breast tumors [5,8].
NAC for breast cancer has a pathologic complete response
(pCR) rate of approximately 30% [6,9,10] and a clinicalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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In contrast, NAC is ineffective in approximately half of all
patients, and many experience toxicity. Therefore, it
would be advantageous to identify patients with chemo-
sensitive tumors before initiating NAC, to avoid potential
therapy-related complications and an inappropriate delay
of surgical treatment.
NAC has numerous advantages, including the provision
of pathological response data that can be used as a surro-
gate marker for long-term clinical outcomes [11,12].
Also, the assessment of responsiveness to NAC allows
the evaluation of potential predictive molecular markers
for chemosensitivity. Several biological markers, includ-
ing the estrogen receptor (ER), progesterone receptor
(PgR), HER2, Ki-67, p21, p53, Bcl, multi-drug-resistant
P-glycoprotein, and topoisomerase 2A, have recently
been investigated; however, there exists no clear correl-
ation between the expression of these markers and
chemosensitivity after sequential taxane- and anthracycline-
based chemotherapies [13-17].
Carbonic anhydrase 9 (CA9) is a cell surface enzyme
that catalyzes the reversible hydration of carbon dioxide
to bicarbonate and a proton [18] and maintains pericel-
lular pH homeostasis [19,20]. CA 9 is overexpressed in
response to tumor hypoxia in many common tumor
types [[21-24] and plays a critical role in hypoxia-
associated tumor acidosis [[25-27]. Hypoxia-inducible
factor-1 α (HIF-1 α) binds to the hypoxia-responsive
element present in the promoter regions of CA9 and
up-regulates CA9 expression [24,28]. Hypoxia plays an
important role in tumor progression and chemoresis-
tance in various types of cancer [29-32]. CA9 has been
implicated in the regulation of the micro-environmental
pH in tumor hypoxia. In this retrospective study, we ex-
amined the correlation between CA9 expression and




A total of 102 patients with resectable early-stage breast
cancer, which was considered to be stage IIA (T2 N0 M0),
IIB (T2 N1 M0 or T3 N0 M0), or IIIA (T3 N1 M0), were
treated with NAC from 2004 to 2009. Breast cancers were
confirmed histopathologically by core needle biopsy
(CNB) and were staged by computed tomography and
bone scan. The clinicopathologic features of the 102
breast cancers are shown in Additional file 1: Table S1.
The clinical stage was based on the TNM Classification of
Malignant Tumors, 6th Edition [33]. No patients had evi-
dence of distant metastasis at the time of surgery. All of
the cases received neoadjuvant chemotherapy consisting
of 4[cycles of 5-fluorouracil (5FU) 500 mg/m2, epirubicin
75 or 100 mg/m2, and cyclophosphamide 500 mg/m2(FEC) followed by 12 cycles of weekly paclitaxel 80 mg/
m2 (wPTX). Sixteen of 102 patients showed HER2-
positive breast cancer, and were administered weekly
trastuzumab with wPTX. Patients underwent mastec-
tomy or breast-conserving surgery after NAC. All pa-
tients who underwent breast-conserving surgery were
administered postoperative radiotherapy. Overall survival
time was set in days as the period from the initiation of
NAC. DFS (disease-free survival) was defined as freedom
from all local, regional, or distant recurrence. All patients
were followed by physical examination, ultrasonography,
computed tomography and bone scan. The median follow-
up period was 6.2 months. This study was conducted with
the approval of the ethical committee of Osaka City
University, and written informed consent was obtained
from all patients.
Assessment of clinical and pathological responses to NAC
Clinical response of the primary tumor was assessed by
ultrasonography, computed tomography, and physical
examination after NAC. Clinical responses were classified
according to the WHO criteria [34]. After NAC, patients
underwent appropriate surgery. The clinical response to
preoperative chemotherapy was determined from the two
diameters measurable in two dimensions by multiplying
the longest diameter by the greatest perpendicular diam-
eter and was classified as follows. Clinical complete re-
sponse (cCR) was judged as the disappearance of all
known disease determined by two observations not less
than four weeks apart. Clinical partial response (cPR) was
a 50% or greater decrease in total tumor lesions. Clinical
no change (cNC) was a less than 50% decrease in total
tumor size, without a 25% increase in tumor size. Clinical
progressive disease (cPD) was defined as a 25% or greater
increase in the tumor size, or the appearance of new le-
sions. The first two categories, cCR and cPR, were judged
as effective. Pathological responses of the tumor and dis-
sected lymph nodes were classified according to the
evaluation criteria of the Japanese Breast Cancer Society
(JBCS) [35], using a 5 histological-grade scale (Grades 0,
1a, 1b, 2, and 3) as follows: Grade 0, no response or al-
most no change in cancer cells after treatment; Grade 1,
slight response; Grade 1a, mild response, mild change in
cancer cells regardless of the area, or marked changes in
cancer cells in less than one-third of total cancer cells;
Grade 1b, moderate response, marked changes in one-
third or more but less than two-thirds of tumor cells;
Grade 2, marked response or marked changes in two-
thirds or more of tumor cells; and Grade 3, no residual
tumor cells, necrosis or disappearance of all tumor cells,
or replacement of all cancer cells by granuloma-like and/
or fibrous tissue. pCR (pathological complete response)
was defined as the complete disappearance of infiltrates,
including lymph node infiltrates. Tumors with residual
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Marked changes approaching a complete response with
only a few remaining cancer cells were classified as near
pCR [36,37]. The others were classified in the non-pCR
group.
Immunohistochemical examinations
All patients underwent a CNB before NAC, and an oper-
ation consisting of mastectomy or conserving surgery with
axillary lymph node dissection after NAC at Osaka City
University. Tissues from each patient were fixed in buffered
formalin and embedded in paraffin. Serial tissue sections of
4 μm thickness were stained with hematoxylin-eosin and
used for immunohistochemical staining. Expressions of
CA9, estrogen receptor (ER), progesterone receptor (PgR),
and HER2 were assessed by immunohistochemistry. After
the paraffin sections were deparaffinized, they were heated
for 20 min at 105°C by autoclave in Target Retrieval Solu-
tion (Dako, Carpinteria, CA). After blocking with 10% goat
serum, the slides were incubated with the primary mono-
clonal antibodies against each of CA9 (clone M75, 1:1000;
Novus Biologicals), ER (clone 1D5, dilution 1:80; Dako,
Cambridge, UK), PgR (clone PgR636, dilution 1:100; Dako),
and HER2 (Hercep Test, Dako) overnight at 4 °C. Peroxid-
ase was introduced using a streptavidin conjugate and then
peroxidase reactivity was visualized using a DAB solution,
followed by counterstaining with haematoxylin.
Immunohistochemical assessment
Immunohistochemical scoring was graded by trained pa-
thologists (Masahiko Ohsawa and Kenichi Wakasa, De-
partment of Diagnostic Pathology). The stroma was
excluded from the staining evaluation. All staining was
scored by counting the number of positive-stained cells,
and was expressed as a percentage of the 1000 tumor
cells counted across several representative fields of the
section using a standard light microscope equipped with
a × 100 square graticule. The reproducibility of counting
was assessed by a second investigator. The cut-off for ER
positivity and PgR positivity was ≥1% positive tumor
cells with nuclear staining. HER2 was graded in four
steps according to the accepted scheme: 0, 1+, 2+, 3+.
HER2 was considered to be positive if immunostaining
was 3+ or if a 2+ result showed gene amplification by
fluorescent in situ hybridization. The ER, PR, and HER2
stainings were evaluated as described in previous reports
[38]. The CA9 antibody intensely stained the mem-
branes of cancer cells. Scores were applied as follows:
score 0, negative staining in all cells; score 1+, weakly
positive or focally positive staining in <10% of the cells;
score 2+, moderately positive staining covering >10% of
the cells; and score 3+, strongly positive staining in >10%
of the cells (Figure 1). CA9 expression was considered
positive for scores of 2+ or 3 + .Statistical analysis
Statistical analysis was performed using SPSS 13.0 statis-
tical software (SPSS Inc., Chicago, IL). The association
between the expression of CA9 and clinicopathological
parameters was analyzed with the chi-square test. Binary
logistic regression was used for multivariate analyses to
identify independent prognostic factors for a pathological
complete response. The Kaplan-Meier method was used
to estimate the values of DFS. DFS was compared using a
log-rank test. The Cox regression model was used for
multivariate analysis of prognostic factors. In all of the
tests, a p value less than 0.05 was considered to be statis-
tically significant.
Results
Clinicopathological responses of breast cancers to NAC
The cCR rate was 17% (18/102), cPR was 61% (62/102),
cNC was 20% (20/102), and cPD was 2% (2/102). There-
fore, the clinical responders (cCR + cPR) made up 78%
(80/102) of the patients. The pathological response was
evaluated using resected tissue after NAC. Of the tumors
investigated, 12% (12/102) were histological response
grade 1a, 33% (34/102) were grade 1b, 20% (20/102) were
grade 2a, 16% (16/102) were grade 2b, and 20% (20/102)
were grade 3. Patients were classified into pathologic re-
sponders (grade 2 and 3; 55% of all patients) and non-
responders (grade 1; 45%) according to the grade of the
tumor. The pCR rate was 29% (30/102). The DFS of
pathologic non-responders was significantly (p = 0.01)
shorter than that of pathologic responders, while no sig-
nificant difference in DFS was found between clinical
non-responders and clinical responders (Figure 2).
Association between clinicopathological parameters and
CA9 expression in CNB specimens
The CA9 expression of primary breast tumors before
NAC was analyzed using CNB specimens. Of the 102
breast cancer patients, 47 patients (46%) had CA9-positive
breast tumors, while 55 (54%) had CA9-negative tumors.
Table 1 shows the correlation between clinicopathological
parameters and CA9 expression in breast cancers. The
CA9 expression in CNB specimens was significantly cor-
related with lymph node metastasis (70%, p = 0.001) and
lymphatic invasion (69%, p = 0.003). The pCR rate of
CA9-positive tumors (23%, 7/30) was significantly lower
(p = 0.003) than that of CA9-negative tumors (77%, 23/
30). The pathological non-responder tumors showed sig-
nificantly more frequent CA9 expression than the patho-
logical responder tumors (p < 0.001). Clinical response
(cCR + cPR) was not associated with CA9 expression (p =
0.062). Recurrent tumors were observed in 28 of 102 pa-
tients. CA9 expression was significantly more frequent
(p < 0.001) in patients with recurrent tumors (79%, 22/28)
than in those with non-recurrent tumors (34%, 25/74).
Figure 1 Immunohistochemical determination of CA9 expression. The positivity of a tumor for CA-9 was semi-quantitatively analyzed
according to the percentage of cells showing membrane positivity. Score 0, negative staining in all cells; score 1+, weakly positive or focally
positive staining in <10% of the cells; score 2+, moderately positive staining covering >10% of the cells; and score 3+, strongly positive staining,
including >10% of the cells.
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sion and other clinicopathological factors.
The correlation between the pCR and the pathological or
clinical response.
We examined the correlation between the pathological
response (pCR vs non-pCR) and pathological or clinical
response (Table 2). A pathological response was signifi-
cantly (p < 0.001) associated with pCR, and a clinical re-
sponse was also significantly (p = 0.018) associated with
pCR.
Association between CA9 and pathological complete
response in CNB specimens
Univariate analysis revealed that the expressions of
CA9, ER, and PgR in CNB specimens were significantlyFigure 2 Association between clinicopathologic response and disease
significantly (p = 0.002) shorter than that in pathologic responders, while th
survival (p = 0.78).associated with pCR. There was no significant associ-
ation between pCR and the other clinicopathological
factors. Multivariate analysis revealed that only CA9 ex-
pression was significantly associated with pCR (Table 3).
Correlation between clinicopathological parameters and
disease-free survival
CA9 expression of breast tumors was analyzed using both
CNB specimens and resected tissues. Since 30 of the 102
breast tumors showed a pathological complete response,
these cases were excluded from the evaluation of CA9 ex-
pression. CA9 expression was therefore examined in 72
resected tissues after NAC. DFS in patients with CA9-
positive tumors was significantly shorter than that in those
with CA9-negative tumors in both samples (CNB speci-
mens and resected tissues) (Figure 3). Univariate analysis-free survival. Disease-free survival in pathologic non-responders was
e clinical response was not associated with disease-free
Table 1 Correlations between CA9 expression and clinicopathological parameters in CNB of 102 primary breast cancers
CA9 expression
Parameter Positive Negative
(n = 47) (n = 55) p-value
Age
≥55 21 (42%) 29 (58%)
<55 26 (50%) 26 (50%) 0.418
Menopause
Positive 31 (44%) 40 (56%)
Negative 16 (52%) 15 (48%) 0.459
Intrinsic subtype
Luminal 22 (48%) 24 (52%)
Luminal-HER 4 (50%) 4 (50%)
HER2 4 (24%) 13 (76%) 0.209
Triple-negative 17 (55%) 14 (45%)
Tumor size
≥ 4 cm 12 (67%) 6 (33%)
< 4 cm 35 (42%) 49 (58%) 0.053
Lymph node status
Positive 23 (70%) 10 (30%)
Negative 24 (35%) 45 (65%) 0.001
Lymph-vascular invasion
Positive 20 (69%) 9 (31%)
Negative 27 (37%) 46 (63%) 0.003
Nuclear grade (NG)
NG1 32 (43%) 42 (57%)
NG 2&3 15 (54%) 13 (46%) 0.350
Pathological response
pCR 7 (23%) 23 (77%)
Non-pCR 40 (56%) 32 (44%) 0.003
Responder (histological grade 2&3) 16 (29%) 40 (71%)
non-Responder (histological grade 1) 31 (67%) 15 (33%) <0.001
Clinical response
Responder (cCR + cPR) 33 (41%) 47 (59%)
non-Responder (cNC + cPD) 14 (64%) 8 (36%) 0.062
Recurrence
Yes 22 (79%) 6 (21%)
No 25 (34%) 49 (66%) <0.001
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expression in resected tissues, tumor size, lymph node
status, and pathological response were significantly asso-
ciated with DFS. There was no significant association be-
tween DFS and clinical response. Multivariate regression
analyses indicated that CA9 expression in resected tis-
sues after NAC was an independent prognostic factor for
DFS (Table 4).Discussion
In recent years, NAC has been adopted as one of the
standard care regimens for primary resectable early-
stage breast cancer. In such cases, the NAC generally
consists of an anthracycline-containing regimen and tax-
ane [4,5]. The evaluation of the tumor response to NAC
is important to determine the appropriate post-operative
chemotherapeutic regimen for patients with recurrent




Responder (histological grade 2&3) 30 26
non-Responder (histological grade 1) 0 46 p < 0.001
Clinical response
Responder (cCR + cPR) 28 52
non-Responder (cNC + cPD) 2 20 p = 0.018
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survival response and pathological response in neoadju-
vant trials—i.e., the cTMN, Fisher’s, Chevailler’s, and
JBCS systems—and all of these have been shown to yield
basically comparable results [39]. In this study, we used
the WHO and JBCS classifications as the therapeutic re-
sponse criteria. The pCR rate was 29% (30/102), and the
response rate was 78% (80/102). These response rates
were similar to those previously reported [6,9,10].
The correlation between chemosensitivity and survival
remains controversial. Some papers have reported that
the prognostic factors included the clinical and patho-
logical response to primary chemotherapy. On the otherTable 3 Univariate and multivariate analyses of the patholog
Parameter Univariate analysis
Odds ratio 95% CI
CA9 expression in CNB
positive vs negative 0.24 0.09-0.63
ER
positive vs negative 0.24 0.10-0.61
PgR
positive vs negative 0.22 0.08-0.61
HER2
positive vs negative 1.75 0.68-4.48
Molecular subtypes
HR+/HER2- vs others 0.33 0.13-0.83
HR-/HER2+ vs others 0.02 0.01-2999894
HR-/HER2+ vs others 1.75 0.683-4.483
HR-/HER2- vs others 1.17 0.93-1.46
Age
≥55 vs <55 0.88 0.37-2.05
Menopause
positive vs negative 0.82 0.33-2.05
Tumor size
≥4 cm vs <4 cm 0.64 0.19-2.12
Lymph node status
positive vs negative 4.33 0.93-20.1hand, at least one paper has reported that response clas-
sifications were inadequate as prognostic markers of the
long-term outcome after NAC [39]. Our data indicated
that clinical response was not a significant predictor of
DFS. Although clinical examination provides approxi-
mate indicators of chemotherapy responses, histopatho-
logic examination of specimens after chemotherapy is
important to evaluate the accurate response or the prog-
nosis [40-43]. A tumor diagnosed as showing a complete
clinical response sometimes retains residual carcinoma
cells by microscopic examination; conversely, a palpable
residual mass may show fibrosis without cancer cells
[42,43]. These findings might explain why the associationical complete response in 102 breast cancers
Multivariate analysis
p value Odds ratio 95% CI p value
0.041 0.21 0.07-0.59 0.003
0.002 0.23 0.02-2.37 0.219
0.004 0.36 0.10-1.30 0.120
0.244








Figure 3 Disease-free survival of patients based on CA-9 expression. The Kaplan-Meier survival curve shows the disease-free survival in
relation to the CA-9 expression. A statistically significant difference in the survival was observed between the CA-9-positive and CA-9-negative
groups in both CNB specimens and resected tissues (log-rank, p = 0.01 and p = 0.03, respectively).
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cally significant than that between pathological response
and DFS in our study.
Our data indicated that pathological response was a
ignificant predictor of the DFS. In this study, FEC
followed by wPTX was the only NAC regimen used for
patients with resectable early-stage breast cancer. How-
ever, the variety of chemotherapy regimens used as NACTable 4 Univariate and multivariate analysis of disease-free s
Parameter Univariate analysi
Odds ratio 95% CI
CA9 expression in CNB specimens
positive vs negative 4.44 1.80-10.9
CA9 expression in resected tissues
positive vs negative 2.63 1.21-5.70
Tumor size
≥ 4 cm vs < 4 cm 2.46 1.11-5.45
Lymph node status
N1-3 vs N0 3.00 1.42-6.35
Lymph-vascular invasion
positive vs negative 4.22 1.99-8.92
ER
positive vs negative 0.91 0.43-1.94
PgR
positive vs negative 0.95 0.45-2.02
HER2
positive vs negative 1.36 0.59-3.11
Clinical response
Responder vs non-responder 0.88 0.37-2.08
Pathological response
Responder vs non-responder 0.29 0.12-0.67
pCR vs non-pCR 0.19 0.45-0.81in previous reports might have been a factor in produ-
cing these inconsistent results.
CA9, a hypoxia-associated endogenous protein, has
been implicated in the regulation of the hypoxic micro-
environment [44,45]. CA9 is considered to be one of the
cellular biomarkers of hypoxic regions in solid tumors.
In the present analysis, CA9 was positive in CNB speci-
mens from 47 (46%) of 102 patients, similar to the ratiourvival
s Multivariate analysis
p value Odds ratio 95% CI p value
0.001 2.32 0.88-6.08 0.089
0.014 2.39 1.04-5.49 0.041
0.026 1.61 0.65-3.97 0.302
0.004 0.97 0.38-2.47 0.955





0.004 1.03 0.38-2.78 0.953
0.024 1.34 0.27-6.62 0.722
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cantly associated with lymph node status and lymph-
vascular invasion. CA9 has been shown to maintain the
survival of breast tumor cells under hypoxic conditions
[47]. Breast cancer cells under hypoxic conditions might
be associated with aggressive tumor phenotypes, which
may indicate a poor prognosis for patients with CA9-
positive breast cancer, as suggested in previous studies
[29,30,48-50].
Tan et al. reported that CA9 in basal-like breast tu-
mors was associated with resistance to chemotherapy
(cyclophosphamide, methotrexate and 5-fluorouracil
(CMF) or adriamycin and cyclophosphamide (AC)) and
poor prognosis [30]. In our present analysis of 31 triple-
negative breast cancers, the DFS of patients with CA9-
positive tumors was significantly shorter (p = 0.015) than
that of patients with CA9-negative tumors (Additional
file 2: Figure S1). The chemosensitivity of triple-negative
breast cancer patients with CA9 was significantly lower
than that of the CA9-negative cases (Additional file 1:
Table S2). CA9 might be a useful biomarker for chemo-
therapy in triple-negative breast cancer. Supuran and
colleagues found that selective CA9 inhibitors inhibited
cell migration and spreading of breast cancer cells in the
absence of oxygen, suggesting that CA9 is a pivotal tar-
get for antitumor therapy in patients with breast carcin-
oma [25,51]. These findings suggest that CA9 inhibitors
followed by wPTX chemotherapy might be useful in
cases of breast carcinoma with resistance to FEC.
Biological markers predicting chemosensitivity have
been evaluated in several studies, but there is still no
clinically useful marker. ER- or PR-positive patients
showed lower pCR rates after NAC than ER- or PR-
negative patients. The pCR rate of CA9-positive tumors
in CNB specimens was significantly lower than that of
CA9-negative tumors. Multivariate analysis revealed that
CA9 expression before NAC was an independent pre-
dictive factor for pCR. An extensive hypoxic microenvir-
onment as determined by CA9 expression in breast
cancer might play a significant role in the resistance to
chemotherapy. These results may indicate that CA9 ex-
pression in CNB specimens is a useful marker for pre-
dicting chemosensitivity to NAC.
We also examined the correlation of CA9 expression
between CNB tissues and resected tissues in the 72 patients.
Although no significant correlation of CA9 staining was ob-
served between the two groups, CA9 expression in resected
tissues showed a tendency (p = 0.081) toward association
with that in CNB tissues (Additional file 1: Table S3). CA9
expression after NAC (67%) was higher than that before
NAC (46%). CA9-positive cells were observed more
frequently in tumor specimens than in CNB specimens.
Eleven of 32 patients with CA9-negative tumors before
NAC were found to have CA9-positive tumors afterNAC. NAC was thus effective in reducing CA9-negative
cells, and resulted in an increase in hypoxic CA9-positive
cells. Twenty-three of 55 patients with CA9-negative
tumors before NAC achieved pCR, and could not be
enrolled in the CA9 expression analysis because there
was no tumor involvement detected in the resected
tissues. These changes in CA9 expression before and
after NAC might be one of the reasons for the lack of a
significant correlation between the CA9 expression in
CNB tissues and that in resected tissues.
CA9 expression in resected tissues after NAC was
correlated with both prognosis and recurrence. In addition,
multivariate regression analyses indicated that the
CA9 expression level after NAC was an independent
prognostic factor for DFS. Thus, CA9 expression after
NAC may be a clinically informative prognostic marker
for breast cancer patients treated with NAC. On the
other hand, CA9 expression before NAC in CNB
specimens may be a useful surrogate marker for pre-
dicting chemosensitivity. Our results indicate that the
hypoxic marker CA9 in CNB specimens could be used
to predict chemosensitivity, and that high expression
of CA9 in resected tissue is correlated with worse
outcomes in patients treated with FEC followed by wPTX
chemotherapy.Conclusion
Hypoxic microenvironment as determined by CA9 ex-
pression in breast cancer might play a significant role in
the resistance to chemotherapy, which indicates that
CA9 expression in CNB specimens is a useful marker
for predicting chemosensitivity to NAC. CA9 expression
in resected tissue is prognostic of DFS in patients with
resectable early-stage breast cancer treated by sequential
FEC and weekly paclitaxel prior to resection.Additional files
Additional file 1: Table S1. Clinicopathologic features of 102 breast
cancers. Table S2. Correlations between CA9 expression and
chemosensitivity in 31 triple-negative breast cancers. Table S3. Correlation
of CA9 expression before NAC to that after NAC in the 72 patients who
did not achieve pCR.
Additional file 2: Figure S1. Disease-free survival of patients based on
CA-9 expression in 31 cases of triple-negative breast cancer. Among the
cases of triple-negative breast cancer, the DFS of patients with CA9-
positive tumors was significantly shorter (p = 0.015) than that of patients
with CA9-negative tumors. (TIFF 25 kb)Abbreviations
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epirubicin + cyclophosphamide; HER2: Human epidermal growth factor
receptor 2; IHC: Immunohistochemistry; NAC: Neoadjuvant chemotherapy;
NC: No change; OS: Overall survival; PgR: Progesterone receptor; PR: Partial
response; PD: Progressive disease; pCR: Pathologic complete response.
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